Viracta Therapeutics (NASDAQ:VIRX) Stock Rating Reaffirmed by Oppenheimer

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “outperform” rating reissued by stock analysts at Oppenheimer in a note issued to investors on Wednesday, Benzinga reports. They currently have a $13.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Viracta Therapeutics in a report on Tuesday.

Viracta Therapeutics Trading Up 31.0 %

VIRX stock traded up $0.22 during mid-day trading on Wednesday, hitting $0.94. 190,591 shares of the company were exchanged, compared to its average volume of 113,969. The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $0.70. The stock has a market capitalization of $36.77 million, a PE ratio of -0.68 and a beta of 0.93. Viracta Therapeutics has a 1-year low of $0.43 and a 1-year high of $2.38.

Viracta Therapeutics (NASDAQ:VIRX) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.05). Equities research analysts expect that Viracta Therapeutics will post -1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VIRX. Geode Capital Management LLC increased its stake in Viracta Therapeutics by 3.0% in the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after acquiring an additional 6,502 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Viracta Therapeutics by 65.5% in the third quarter. Cubist Systematic Strategies LLC now owns 22,371 shares of the company’s stock valued at $96,000 after acquiring an additional 8,854 shares during the last quarter. Renaissance Technologies LLC increased its stake in Viracta Therapeutics by 7.6% in the second quarter. Renaissance Technologies LLC now owns 134,799 shares of the company’s stock valued at $190,000 after acquiring an additional 9,500 shares during the last quarter. Bank of America Corp DE increased its stake in Viracta Therapeutics by 81.3% in the first quarter. Bank of America Corp DE now owns 23,241 shares of the company’s stock valued at $37,000 after acquiring an additional 10,422 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Viracta Therapeutics by 2.8% in the second quarter. BlackRock Inc. now owns 460,235 shares of the company’s stock valued at $649,000 after acquiring an additional 12,434 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.